Top

International Journal of Colorectal Disease

Published in:

01-03-2007 | Original Article

Differential expression of toll-like receptor 3 and 5 in ileal pouch mucosa of ulcerative colitis patients

Authors: Gundi Heuschen, Christine Leowardi, Ulf Hinz, Frank Autschbach, Andreas Stallmach, Christian Herfarth, Udo A. Heuschen

Published in: International Journal of Colorectal Disease | Issue 3/2007

Abstract

Background and aims

The pathogenesis of pouchitis, major complication after restorative proctocolectomy, and ileal J pouch-anal anastomosis (IPAA) in patients with ulcerative colitis (UC) is still unclear. Changes in intraluminal bacterial colonization and correlated changes of pouch mucosa are thought to play an important role. Toll-like receptors (TLRs) as part of the innate immune system are capable of recognizing bacterial antigens. Their activation can lead to secretion of proinflammatory mediators. In this study, TLR2, 3, 4, and 5 expression profiles in the pouch mucosa of patients with UC and IPAA were analyzed and correlated with pouchitis.

Materials and methods

Clinical symptoms, endoscopy, and histology were assessed in 35 patients using the Heidelberg Pouchitis Activity Score to classify patients as either having pouchitis or not. TLR mRNA expression in normal ileal mucosa and pouch mucosa was investigated by performing semi-quantitative reverse transcriptase polymerase chain reaction (RT-PCR). The results of RT-PCR were associated with the pouchitis score.

Results

In the analysis of all patients, TLR3 expression was decreased significantly whereas TLR5 expression was increased significantly in pouch mucosa compared to normal ileal mucosa (p-values 0.0076 and 0.016, respectively). A more detailed analysis upon dividing the patients into patients with and without pouchitis showed decreased TLR3 expression in the pouch mucosa only of patients without pouchitis (p-value=0.0067). TLR5 expression was increased in the pouch mucosa only of patients with pouchitis (p-value=0.023). No differences in TLR2 and 4 expression were found in either group.

Conclusion

Differential expression of TLR3 and 5 suggests bacterial involvement in the pathogenesis of pouchitis in patients with UC.

Sandborn WJ (1994) Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis and treatment. Gastroenterology 107:1856–1860PubMed

Nicholls RJ, Banerjee AK (1998) Pouchitis: risk factors, etiology and treatment. World J Surg 22:347–351PubMedCrossRef

Meagher AP, Farouk R, Dozois RR, Kelly KA, Pemberton JH (1998) J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg 85:800–803PubMedCrossRef

Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF (1994) Pouchitis after ileal pouch-anal anastomosis: a pouchitis disease activity index. Mayo Clin Proc 69:409–415PubMed

Shen B, Achkar JP, Lashner BA, Ormsby AH, Remzi FH, Bevins CL, Brezinski A, Petras RE, Fazio VW (2001) Endoscopic and histologic evaluation together with symptom assessment are required to diagnose pouchitis. Gastroenterology 121:261–267PubMedCrossRef

Heuschen UA, Autschbach F, Allemeyer EH, Zöllinger AM, Heuschen G, Uehlein T, Herfarth C, Stern J (2001) Long-term follow-up after ileoanal pouch procedure. Dis Colon Rectum 44:487–499PubMedCrossRef

Heuschen UA, Allemeyer EH, Hinz U, Autschbach F, Uehlein T, Herfarth C, Heuschen G (2002) Diagnosing pouchitis. Dis Colon Rectum 45:776–788PubMedCrossRef

Rauh SM, Schoetz DJ, Roberts PL, Murray JJ, Coller JA, Veidenheimer MC (1991) Pouchitis—is it a wastebasket diagnosis? Dis Colon Rectum 34:685–689PubMedCrossRef

Luukkonen P, Järvinen H, Tanskanen M Kahri M (1994) Pouchitis—recurrence of inflammatory bowel disease? Gut 35:243–246PubMed

10.

Nygaard K, Bergan T, Bj0rneklett A, Hoverstad T, Lassen J, Aase S (1994) Topical metronidazole treatment in pouchitis. Scand J Gastroenterol 29:462–467PubMed

11.

Campierei M, Gionchetti P (1999) Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? Gastroenterology 116:1246–1260CrossRef

12.

Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M (2000) Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119:305–309PubMedCrossRef

13.

Madden MV, McIntyre AS, Nicholls RJ (1994) Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 39:1193–1196PubMedCrossRef

14.

Madsen K, Cornish A, Soper P, McKaigney C, Humberto J, Yachimec C, Doyle J, Jewell L, de Simone C (2001) Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121:580–591PubMedCrossRef

15.

Sartor RB (2000) Probiotics in chronic pouchitis: restoring luminal microbial balance. Gastroenterology 119:584–587PubMed

16.

Ruseler-van Embden JG, Schouten WR, van Lieshout LM (1994) Pouchitis: result of microbial imbalance? Gut 35:658–664PubMed

17.

Fiocchi C (1998) Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115:182–205PubMedCrossRef

18.

Sartor RB (1995) Microbial factors in the pathogenesis of Crohn’s disease, ulcerative colitis and experimental intestinal inflammation. In: Kirsner JB, Shorter RG (eds) Inflammatory bowel disease, 4th edn. Williams & Wilkins, Baltimore, MD, pp 96–124

19.

Cario E, Rosenberg IM, Brandwein SL, Beck PL, Reinecker HC, Podolsky DK (2000) Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell-lines expressing Toll-like receptors. J Immunol 164:966–972PubMed

20.

Modlin RL (2002) Mammalian Toll-like-receptors. Ann Allergy Asthma Immunol 88:543–554PubMedCrossRef

21.

Underhill DM, Ozinsly A (2002) Toll-like-receptors: key mediators of microbe detection. Curr Opin Immunol 14:103–110PubMedCrossRef

22.

Qureshi ST, Gros P, Malo D (1999) Host resistance to infection: genetic control of lipopolysaccharide responsiveness by TOLL-like receptors genes. Trends Genet 15:291–294PubMedCrossRef

23.

Kopp EB, Medzhitov R (1999) The Toll-receptor family and control of innate immunity. Curr Opin Immunol 11:13–18PubMedCrossRef

24.

Anderson KV (2000) Toll signaling pathways in the innate immune response. Curr Opin Immunol 12:13–19PubMedCrossRef

25.

Lien E, Sellati TJ, Yoshimura A, Flo TH, Rawadi G, Finberg RW, Carroll JD, Espevik T, Ingalls RR, Radolf JD, Golenbock DT (1999) Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J Biol Chem 274:33419–33425PubMedCrossRef

26.

Yang RB, Mark MR, Gurney AL, Godowsky PJ (1999) Signaling events by lipopolysaccharide-activated toll-like-receptor 2. J Immunol 163:639–643PubMed

27.

Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K, Akira S (1999) Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell-wall components. Immunity 11:443–451PubMedCrossRef

28.

Beutler B (2000) TLR4: central component of the sole mammalian LPS sensor. Curr Opin Immunol 12:20–26PubMedCrossRef

29.

Alexopoulou L, Czopik Holt A, Medzhitov R, Flavell RA (2001) Recognition of double-stranded RNA and activation of NFκB by Toll-like receptor 3. Nature 413:732–738PubMedCrossRef

30.

Gewirtz AT, Navas TA, Lyons S, Godowski PJ, Madara JL (2001) Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol 167:1882–1885PubMed

31.

Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A (2001) The innate immune response to bacterial flagellin is mediated by Toll-like-receptor 5. Nature 410:1099–1103PubMedCrossRef

32.

Mizel SB, Snipes JA (2002) Gram-negative flagellin-induced self-tolerance is associated with a block in interleukin-1 receptor-associated kinase release from Toll-like receptor 5. J Biol Chem 277:22414–22420PubMedCrossRef

33.

Brightbill HD, Libraty DH, Krutzik SR, Yang RB, Belisle JT, Bleharski JR, Maitland M, Norgard MV, Plevy SE, Smale ST, Brennan PJ, Bloom BR, Godowski PJ, Modlin RL (1999) Host defense mechanisms triggered by microbial lipoproteins through toll-like-receptors. Science 285:732–736PubMedCrossRef

34.

Aliprantis AO, Yang RB, Mark MR, Suggett S, Devaux B, Radolf JD, Klimpel GR, Godowski P, Zychlinsky A (1999) Cell activation and apoptosis by bacterial lipoproteins through Toll-like-receptor-2. Science 285:736–739PubMedCrossRef

35.

Thoma-Uszynski S, Stenger S, Takeuchi O, Ochoa MT, Engele M, Sieling PA, Barnes PF, Rollinghoff M, Bolcskei PL, Wagner M, Akira S, Norgard MV, Belisle JT, Godowski PJ, Bloom BR, Modlin RL (2001) Induction of direct antimicrobial activity through mammalian toll-like-receptors. Science 291:1544–1547PubMedCrossRef

36.

Aliprantis AO, Yang RB, Weiss DS, Godowski P, Zychlinsky A (2000) The apoptotic signaling pathway activated by Toll-like-receptor 2. EMBO J 19:3325–3336PubMedCrossRef

37.

Abreu M, Vora P, Faure E, Thomas L, Arnold E, Arditi M (2001) Decreased expression of TLR4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol 167:1609–1616PubMed

38.

Smith PD, Smythies LE, Mosteller-Barnum M, Sibley DA, Russell MW, Merger M, Sellers MT, Orenstein JM, Shimada T, Graham MF, Kubagawa H (2001) Intestinal macrophages lack CD14 and CD89 and consequently are down-regulated for LPS- and IgA-mediated activities. J Immunol 167:2651–2656PubMed

39.

Supajatura V, Ushio H, Nakao A, Okumura K, Ra C, Ogawa H (2001) Protective roles of mast cells against enterobacterial infection are mediated by Toll-like receptor 4. J Immunol 167:2250–2256PubMed

40.

Naik S, Kelly EJ, Meijer L, Petterson S, Sanderson IR (2001) Absence of Toll-like receptor 4 explains endotoxin hyporesponsiveness in human intestinal epithelium. J Pediatr Gastroenterol Nutr 32:449–453PubMedCrossRef

41.

Cario E, Podolsky DK (2000) Differential alteration in intestinal epithelial cell expression of TLR3 and TLR4 in inflammatory bowel disease. Infect Immun 68:7010–7017PubMedCrossRef

42.

Hausmann M, Kiessling S, Mestermann S, Webb G, Spöttl T, Andus T, Schölmerich J, Herfarth H, Ray K, Falk W, Rogler G (2002) Toll-like-receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology 122:1987–2000PubMedCrossRef

43.

Pasquali D, Bellastella A, Valente A, Botti G, Capasso I, del Vecchio S, Salvatore M, Colantuoni V, Sinisi AA (1997) Retinoic acid receptors alpha, beta and gamma, and cellular retinol binding protein-I expression in breast fibrocystic disease and cancer. Eur J Endocrinol 137:410–414PubMedCrossRef

44.

Dieterich KD, Lehnert H (2000) Decreased expression of corticotropin-releasing factor-binding protein mRNA in ACTH-secreting pituitary adenomas. Exp Clin Endocrinol Diabetes 108:59–62PubMed

45.

Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085–2088PubMedCrossRef

46.

Lorenz E, Mira JP, Frees KL, Schwartz DA (2002) Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 162:1028–1032PubMedCrossRef

47.

Franchimont D, Vermeire S, El Housni H, Pierik M, Van Steen K, Gustot T, Quertinmont E, Abramowicz M, Van Gossum A, Devière J, Rutgeerts P (2004) Deficient host–bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299Gly polymorphism is associated with Crohn’s disease and ulcerative colitis. Gut 53:987–992PubMedCrossRef

48.

Muzio M, Polentarutti N, Bosisio D, Prahladan MKP, Mantovani A (2000) Toll-like receptors: a growing family of immune receptors that are differentially expressed and regulated by different leukocytes. J Leukoc Biol 67:450–456PubMed

49.

Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, Targan SR, Fort M, Hershberg RN (2004) Bacterial flagellin is a dominant antigen in Crohn’s disease. J Clin Invest 113:1296–1306PubMedCrossRef

50.

Gitter AH, Wullstein F, Fromm M, Sculzke JD (2001) Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging. Gastroenterology 121:1320–1328PubMedCrossRef

51.

Andreakos E, Foxwell B, Feldmann M (2004) Is targeting TOLL-like receptors and their signalling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? Immunol Rev 202:250–265PubMedCrossRef

Title: Differential expression of toll-like receptor 3 and 5 in ileal pouch mucosa of ulcerative colitis patients
Authors: Gundi Heuschen
Christine Leowardi
Ulf Hinz
Frank Autschbach
Andreas Stallmach
Christian Herfarth
Udo A. Heuschen
Publication date: 01-03-2007
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 3/2007
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-006-0133-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Differential expression of toll-like receptor 3 and 5 in ileal pouch mucosa of ulcerative colitis patients

Abstract

Background and aims

Materials and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background and aims

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2007

Pregnancy and delivery in patients with enterostomy due to anorectal complications from Crohn’s disease

Changes in surgical therapy for Crohn’s disease over 33 years: a prospective longitudinal study

Decrease in rat internal anal pressure with the use of a topical ointment containing a killed E. coli culture suspension

Clinical and manometric results of endorectal advancement flaps for complex anal fistula

The fate of the rectal stump after subtotal colectomy for ulcerative colitis

Stapled transanal rectal resection versus stapled anopexy in the cure of hemorrhoids associated with rectal prolapse. A randomized controlled trial